naa a22 4500 510764533 CHVBK 20180411083152.0 cr unu---uuuuu 180411e20131101xx s 000 0 eng 10.1007/s12094-013-1020-6 doi (NATIONALLICENCE)springer-10.1007/s12094-013-1020-6 VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer [Elektronische Daten] [T. Fleitas, V. Martínez-Sales, V. Vila, E. Reganon, D. Mesado, M. Martín, J. Gómez-Codina, J. Montalar, G. Reynés] Purpose: There is a need for biomarkers that may help in selecting the most effective anticancer treatments for each patient. We have investigated the prognostic value of a set of angiogenesis, inflammation and coagulation markers in patients treated for advanced non-small cell lung cancer. Patients and methods: Peripheral blood samples were obtained from 60 patients before first line platinum-based chemotherapy±bevacizumab, and after the third cycle of treatment. Blood samples from 60 healthy volunteers were also obtained as controls. Angiogenesis, inflammation and coagulation markers vascular endothelial growth factor (VEGF), their soluble receptors 1 (VEGFR1) and 2 (VEGFR2), thrombospondin-1 (TSP-1), interleukin-6 (IL6), sialic acid (SA) and tissue factor (TF) were quantified by ELISA. Results: Except for TSP-1, pre- and post-treatment levels of all markers were higher in patients than in controls (p<0.05). There was a positive and significant correlation between VEGF and VEGFR2 before treatment. VEGF also correlated with inflammatory markers IL-6 and SA. Moreover, there was a positive and significant correlation between levels of VEGFR1 and TF. Decreased levels of TSP-1 and increased levels of VEGF were associated with shorter survival. Bevacizumab significantly modified angiogenesis parameters and caused a decrease of VEGF and an increase of TSP-1. Conclusion: Angiogenesis, inflammation and coagulation markers were increased in NSCLC patients. Increased levels of VEGF and low levels of TSP-1 correlated with a poor prognosis. Federación de Sociedades Españolas de Oncología (FESEO), 2013 Lung cancer nationallicence Tumor angiogenesis nationallicence Inflammation nationallicence Coagulation nationallicence Prognostic markers nationallicence Fleitas T. Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Avda Blasco Ibañez 17, 46010, Valencia, Spain aut Martínez-Sales V. Research Center, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain aut Vila V. Research Center, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain aut Reganon E. Research Center, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain aut Mesado D. Research Center, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain aut Martín M. Department of Medical Oncology, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain aut Gómez-Codina J. Department of Medical Oncology, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain aut Montalar J. Department of Medical Oncology, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain aut Reynés G. Department of Medical Oncology, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain aut Clinical and Translational Oncology Springer Milan 15/11(2013-11-01), 897-902 1699-048X 15:11<897 2013 15 12094 https://doi.org/10.1007/s12094-013-1020-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-013-1020-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Fleitas T. Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Avda Blasco Ibañez 17, 46010, Valencia, Spain aut NATIONALLICENCE 700 1- Martínez-Sales V. Research Center, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain aut NATIONALLICENCE 700 1- Vila V. Research Center, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain aut NATIONALLICENCE 700 1- Reganon E. Research Center, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain aut NATIONALLICENCE 700 1- Mesado D. Research Center, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain aut NATIONALLICENCE 700 1- Martín M. Department of Medical Oncology, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain aut NATIONALLICENCE 700 1- Gómez-Codina J. Department of Medical Oncology, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain aut NATIONALLICENCE 700 1- Montalar J. Department of Medical Oncology, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain aut NATIONALLICENCE 700 1- Reynés G. Department of Medical Oncology, Hospital Universitario y Politécnico La Fe, Avda Campanar 21, 46009, Valencia, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/11(2013-11-01), 897-902 1699-048X 15:11<897 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer